Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer
May 10 2022 - 07:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused
on driving innovation to transform outcomes for cancer patients,
today announced the appointment of Richard Wanstall as Chief
Financial Officer.
“We are pleased to welcome Rick as our Chief Financial Officer
and we look forward to drawing from his notable experience leading
biotech companies through significant organizational growth,” said
Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive
Officer of Oncorus. “Rick is a trusted colleague that I, as well as
other members of the senior leadership team, have had the pleasure
of working alongside in our previous roles. I am confident that his
deep understanding of the biotech industry, specifically his
expertise in life sciences corporate strategy and financing, will
be a vital addition to Oncorus as our business matures. On behalf
of the entire leadership team, we are excited to work with Rick to
achieve our shared goal of meaningfully improving the current
standard of care for cancer patients.”
“I’m excited to join the Oncorus team and to work in tandem with
such a credentialed group of industry leaders to advance the
company’s innovative HSV and selectively self-amplifying vRNA/LNP
platform technologies,” said Mr. Wanstall. “Oncorus is at a
critical time in its development with key data readouts from
ONCR-177 expected later this year, ongoing IND-enabling studies for
ONCR-021, a state-of-the art GMP manufacturing facility nearing
completion and a cash runway into early 2024. Taken together,
Oncorus is uniquely positioned to execute on their viral
immunotherapeutic approach to cancer treatment, and I look forward
to contributing my skillset to drive value for shareholders and
bring this innovative technology to patients in need.”
Mr. Wanstall brings over 25 years of financial and operations
experience to Oncorus. Most recently, he served as Chief Financial
Officer and Treasurer for Aileron Therapeutics, where he was
responsible for overseeing the company’s strategy, finance,
investor relations, and operations activities. Prior to Aileron,
Mr. Wanstall served as Vice President of Finance at Moderna
Therapeutics and as Senior Vice President of Finance at Stream
Global Services. Previously, Mr. Wanstall was Vice President of
Finance at Art Technology Group, a Vice President at Taxware, and
Director of Finance at CNET. He began his career in various
financial roles at John Hancock, Fidelity Investments, and
PricewaterhouseCoopers. Mr. Wanstall holds an M.B.A. from Babson
College and a B.A. in Accounting from Salem State University.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
Herpes Simplex Virus (HSV) and selectively self-amplifying viral
RNA (vRNA) Immunotherapy Platforms.
Designed to deliver next-generation viral immunotherapy impact,
our HSV Platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead HSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering selectively self-amplifying vRNA Immunotherapy Platform,
highlighted by our product candidates ONCR-021 and ONCR-788,
involves a highly innovative, novel combination of RNA and
oncolytic virus-based modalities designed to realize the potential
of RNA medicines for cancer.
Please visit www.oncorus.com to learn more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding Oncorus’ near-term milestones,
including data readouts from the ongoing clinical trial of
ONCR-177, the planned IND submission for ONCR-021, the completion
of Oncorus’ facility in Andover, Massachusetts and the Oncorus’
cash runway. The words “may,” “might,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“expect,” “estimate,” “seek,” “predict,” “future,” “project,”
“potential,” “continue,” “target” and similar words or expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks associated
with: Oncorus’ ability to successfully demonstrate the safety,
tolerability and efficacy of ONCR-177, ONCR-021, ONCR-788 and
ONCR-GBM and obtain regulatory approval thereof; the impact of
COVID-19 on Oncorus’ operations and the timing and anticipated
results of its ongoing and planned clinical trials; Oncorus’
ability to obtain the requisite components for its product
candidates manufactured in accordance with regulatory requirements;
Oncorus’ planned facility consolidation and the expansion of
Oncorus’ in-house manufacturing capabilities; the adequacy of
Oncorus’ existing capital resources and availability of financing
on commercially reasonable terms; the accuracy of the Oncorus’
estimates regarding expenses, future revenue, capital requirements
and needs for additional financing; and Oncorus’ ability to obtain,
maintain and protect its intellectual property. These and other
risks and uncertainties are described in greater detail in the
section entitled "Risk Factors" in Oncorus’ Annual Report on Form
10-K for the year ended December 31, 2021, filed with the
Securities and Exchange Commission (SEC) on March 9, 2022, and
Oncorus’ Quarterly Report on Form 10-Q for the quarter ended March
31, 2022, filed with the SEC on May 4, 2022, as well as discussions
of potential risks, uncertainties, and other important factors in
the other filings that Oncorus makes with the SEC from time to
time. These documents are available under the “SEC filings” page of
the Investors section of Oncorus’ website at
http://investors.oncorus.com. Any forward-looking statements
represent Oncorus’ views only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. Oncorus explicitly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking
statements. Investor
Contact:Stern Investor Relations Julie
SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Mar 2023 to Mar 2024